La bourse est fermée

Denali Therapeutics Inc. (DNLI)

NasdaqGS - NasdaqGS Cours en temps réel. Devise en USD
Ajouter à la liste dynamique
20,52-0,25 (-1,20 %)
À la clôture : 04:00PM EDT
20,54 +0,02 (+0,08 %)
Échanges après Bourse : 06:17PM EDT

Denali Therapeutics Inc.

161 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650-866-8548
https://www.denalitherapeutics.com

Secteur(s)Healthcare
Secteur d’activitéBiotechnology
Employés à temps plein445

Dirigeants clés

NomTitrePayerExercéAnnée de naissance
Dr. Ryan J. Watts Ph.D.Co-Founder, President, CEO & Director1,04M2,17M1976
Dr. Alexander O. Schuth M.D.Co-Founder, CFO, COO & Secretary737,2k601,4k1973
Dr. Marc Tessier-Lavigne Ph.D.Co-Founder & Independent Director58,23kS.O.1960
Dr. Carole Ho M.D.Chief Medical Officer & Head of Development737,2kS.O.1973
Mr. Tyler M. NielsenSenior Vice President of Corporate FinanceS.O.S.O.1978
Dr. Dana AndersenChief Technical and Manufacturing OfficerS.O.S.O.S.O.
Mr. Joe Lewcock Ph.D.Chief Scientific OfficerS.O.S.O.S.O.
Dr. Laura HansenVice President of Investor RelationsS.O.S.O.S.O.
Mr. Chris WalshGeneral CounselS.O.S.O.S.O.
Mr. Mark RowenVice President of Corporate DevelopmentS.O.S.O.S.O.
Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Denali Therapeutics Inc. en date du 1 mars 2024 est 6. Les scores principaux sont Audit : 1; Société : 4; Droits des actionnaires : 8; Compensation : 9.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.